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Summary
Introduction:  Chinese  herbal  medicine  is  an  increasingly  popular  worldwide  medical  therapy
which also  has  an  impact  in  pregnancy.  However,  the  question  of  its  drug  safety  during  pregnancy
remains  unresolved.  Potential  problems  include  teratogenicity,  abortion,  perinatal  toxicity,  pre-
and postnatal  developmental  abnormalities,  and  eventually  an  increased  risk  for  carcinomas  in
the offspring.  Standard  Materia  Medica  textbooks  contain  unreliable  information  when  it  comes
to risks  during  pregnancy.  Wang  and  co-workers  conducted  an  experimental  study  (WS)  on  mice
in which  they  investigated  the  effects  of  17  Chinese  medicinals  regarding  embryotoxicity  and
fetotoxicity.  All  these  drugs  seemed  to  exhibit  multiple  signiﬁcant  toxic  effects.  Another  study
by Li  and  co-workers  (LS)  investigated  the  reproductive  toxicity  of  Atractylodis  macrocephalae
Rhizoma  in  mice,  rats  and  rabbits.  They  described  an  increased  pre-  and  postnatal  mortality
and, at  high  doses,  congenital  malformations.  In  an  attempt  to  identify  the  risks  of  the  tested
medicinals  during  pregnancy,  we  analysed  these  two  experimental  studies  and  compared  their
results with  possible  safety  data  for  humans  from  two  reviews  of  clinical  studies  on  threatened
miscarriage  (AR  and  CR).
Methods:  We  re-evaluated  WS  and  LS  in  relation  to  accordance  with  internationally  accepted
rules, equivalence  to  human  dose,  biometric  accuracy,  plausibility,  and  coherence.  Eligible
studies of  the  two  reviews  on  threatened  miscarriage  were  evaluated  for  speciﬁc  pregnancy
risks concerning  the  17  medicinals  tested  in  WS  and  LS.
Results:  We  found  that  WS  does  not  conform  to  international  ICH  guidelines  and  includes
many inconsistencies,  implausibilities  and  several  severe  biometrical  ﬂaws.  It  reported  a  total
of 364  signiﬁcant  events  out  of  which  145  false  signiﬁcant  results  are  expected.  The  data-
handling pointed  to  irregularities.  Analysis  of  LS  exhibited  also  many  inconsistencies.  The  results
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regarding  congenital  malformations  were  statistically  insigniﬁcant  and  are  based  on  small  case
numbers.  Insofar  as  the  safety  data  of  the  17  medicinals  were  documented  by  eligible  studies
of the  two  reviews,  there  was  no  indication  of  an  increased  abortion  rate  in  humans.  Fetal
growth retardation  was  not  observed  in  the  human  studies.  For  neonatal  health  and  postnatal
development,  there  were  sufﬁcient  safety  data  only  for  a  few  medicinals  in  the  human  studies.
As for  teratogenicity,  only  small  case  numbers  (0  to  109)  were  available  from  the  human  data.
Conclusion:  WS  and  LS  are  not  reliable  data  sources  for  deriving  pregnancy  risks  in  humans  for  the
tested Chinese  medicinals.  In  addition,  the  results  appear  to  contradict  the  outcomes  observed
in the  treatment  of  humans.  Regarding  teratogenicity,  for  most  Chinese  medicinals,  neither  the
safety nor  the  risk  during  pregnancy  can  be  deﬁnitively  ascertained.  Further  studies  on  the  risks
of Chinese  medicinals  during  pregnancy  are  urgently  needed.
© 2014  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Introduction
Chinese  herbal  medicine  (CHM)  is  an  increasingly  popular
medical  therapy  which  is  practiced  world-wide.1,2 Despite
its  ancient  roots,  Chinese  medicine  may  be  able  to  offer
modern  patients  treatment  options  especially  in  cases  in
which  Western  medicine  has  not  been  able  to  provide  sat-
isfactory  clinical  results.3 In  order  to  fulﬁl  its  role  as  a
treatment  option  for  contemporary  patients,  CHM  must  con-
form  to  modern  safety  requirements.  These  are  particularly
crucial  in  the  treatment  of  pregnant  women  because  any
therapy  will  affect  the  health  of  the  developing  embryo  or
foetus,  respectively.  Chinese  medicine  offers  many  treat-
ment  options  for  pregnancy-related  indications  such  as
threatened  abortion,  hyperemesis  gravidarum,  or  intercur-
rent  diseases.  In  treatment  of  patients  for  infertility,  this
may  also  impact  the  course  of  an  undiagnosed  pregnancy
or  any  incipient  pregnancy  occurring  after  successful  treat-
ment.
The  question  of  safety  during  pregnancy  is  already  a  dif-
ﬁcult  one  for  Western  drugs  due  to  insufﬁcient  data.  An
important  concern  is  potential  teratogenic  risks.  Other  pos-
sible  hazards  include  abortion,  perinatal  toxicity,  pre-  and
postnatal  developmental  abnormalities,  and  an  increased
risk  for  carcinomas  for  the  child  later  in  his  or  her  lifetime.
inconsistent  information  when  it  comes  to  risks  during  preg-
nancy.  Examples  of  different  safety  classiﬁcations  of  some
well-known  standard  textbooks4—6 are  provided  in  Table  1.
In  Chen  and  Chen6 which  focuses  on  Chinese  pharmacology,
terms  such  as  embryotoxicity  or  fetotoxicity  appear  only
twice  (in  relation  to  the  plant  substances  Arecae  Semen  and
Arecae  Pericarpium).
In order  to  improve  the  unsatisfactory  situation  concern-
ing  the  available  data  on  pregnancy  risks  of  CHM,  Wang  and
co-workers  conducted  an  experimental  study  (the  ‘‘Wang
study’’,  WS)  in  mice  in  which  they  selected  17  Chinese
medicinals  commonly  used  during  pregnancy  and  adminis-
tered  them  at  different  periods  of  pregnancy.7 Their  effects
regarding  embryotoxicity  and  fetotoxicity  were  then  inves-
tigated.  The  results  caught  the  TCM  community  unaware.
All  the  drugs  investigated  seemed  to  exhibit  multiple  signif-
icant  toxic  effects  for  several  periods  of  drug  administration,
especially  regarding  fetal  resorptions,  stillbirths,  fetal  and
postnatal  deaths,  postnatal  growth  retardation,  and  ter-
atogenicity.  Signiﬁcant  results  for  skeletal  malformations
were  found  for  Rehmanniae  Radix  praeparata,  Chuanxiong
Rhizoma,  and  Citri  reticulati  Pericarpium.  Minor  malforma-
tions  were  found  for  Cuscutae  Semen,  Dipsaci  Radix,  Taxilli
Herba,  Glycyrrhizae  Radix,  Codonopsis  Radix,  Dioscoreae
Radix,  Amomi  Fructus,  Chuanxiong  Rhizoma,  ArtemisiaeStandard  Materia  Medica  textbooks  providing  excellent
information  about  the  properties,  functions  and  actions  of
Chinese  medicinals  contain  unreliable  and  sometimes  even
a
H
ergyi  Folium  and  Citri  reticulatae  Pericarpium  (Table  2).
owever,  the  results  appear  to  show  implausibilities  and  the
ffort  to  re-analyse  the  data  was  considered  justiﬁed.
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Table  1  Statements  regarding  safety  during  pregnancy  in  various  standard  textbooks.
Medicinal  pin  yin  Bensky4 Chen6 Hempen5
Arecae  Semen  bing  lang  —  ca  ci
Coicis Semen  yi  yi  ren  —  ci  ca
Crataegi Fructus  shan  zha  ci  —  al
Lycopi Herba  ze  lan  ca  —  ci
Massa medicata  ferm  shen  qu  —  ca  ci
Plantaginis  Semen  che  qian  zi  ca  —  ci
Siegesbeckiae  Herba xi  xian  cao  -  ca  ci
ci = ‘‘contraindicated during pregnancy’’, ca = ‘‘use with caution during pregnancy’’, al = ‘‘allowed’’, - = no indication of restrictions
during pregnancy.
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the  numbers  of  cases  for  each  medicinal  were  summed-up.Another  study  investigated  the  reproductive  toxicity
f  Atractylodis  macrocephalae  Rhizoma  in  mice,  rats  and
abbits  (the  ‘‘Li  study’’,  LS).8 It  used  the  same  param-
ters  and  time  frames  as  in  WS.  This  study  found  that
he  administration  of  Atractylodis  macrocephalae  Rhizoma
o  mice  was  associated  with  signiﬁcantly  reduced  fetal
rowth,  a  signiﬁcantly  prolonged  duration  of  pregnancy  and
n  increased  prenatal  and  postnatal  mortality.  Furthermore,
t  high  doses,  congenital  malformations  (skeletal,  fetal
ydrops,  and  short  ear  anomaly)  and  fetal  resorptions  were
escribed.  The  study  was  vividly  documented  with  photos  of
he  malformations  in  mice.
To  explore  the  risks  of  using  CHM  during  pregnancy  in
umans,  a  group  of  authors  —  with  the  participation  of
elevant  authors  from  WS  —  conducted  a  review  and  meta-
nalysis  of  adverse  outcomes  in  studies  and  case  series  on
hreatened  miscarriage  (the  ‘‘adverse  outcome  review’’,
R).9 According  to  the  authors,  threatened  miscarriage  is
he  most  common  indication  for  CHM  during  pregnancy  in
hina.  Another  evaluation  of  CHM  in  treating  threatened
iscarriage  is  the  Cochrane  review  on  this  subject  (CR).10
his  review  included  for  the  most  part  different  studies  than
hose  of  AR.
Although  the  methodological  quality  of  most  of  the  tri-
ls  included  in  these  two  reviews  does  not  permit  deﬁnite
onclusions  to  be  drawn,  the  data  from  eligible  studies  can
onetheless  be  used  to  evaluate  potential  pregnancy  risks
f  the  used  medicinals.  Through  an  analysis  of  the  extracted
afety  data  on  humans  and  comparison  with  the  experimen-
al  data  of  the  animal  studies,  this  paper  tries  to  add  to
he  discussion  on  the  safety  of  Chinese  medicines  during
regnancy.
ethods
S  was  analyzed  in  relation  to  accordance  with  inter-
ationally  accepted  rules,  equivalence  to  human  dose,
iometric  accuracy,  plausibility  and  coherence.  Similarly,
S  was  assessed  for  equivalence  of  dosing,  plausibility  and
oherence.
AR  was  evaluated  for  speciﬁc  pregnancy  risks  concerning
he  17  medicinals  tested  in  WS  and  LS.  From  this  review,
e  included  those  studies  which  implied  a  documentation
f  the  respective  pregnancy  risk  and  ensured  a  sufﬁ-
iently  long  observation  time  for  this  scope.  The  following
T
w
tregnancy  risks  were  evaluated  and  compared  with  the
esults  of  WS:  abortion  rate  (in  relation  to  fetal  resorptions
n  WS),  fetal  growth  retardation  and  birth  weight  (in  relation
o  fetal  growth  in  WS),  neonatal  health  and  development
in  relation  to  postnatal  deaths  and  postnatal  weight  gain  in
S)  and  congenital  malformations.  To  ensure  a high  validity,
nly  studies  were  included  which  documented  a  sufﬁcient
ollow-up  time:  for  fetal  growth  retardation  and  birth  weight
he  minimum  time  was  until  delivery,  for  congenital  malfor-
ations,  neonatal  health  and  development  until  the  fourth
ostnatal  week.
We  excluded  studies  which  are  obviously  not  credi-
le  because  there  were  signiﬁcantly  fewer  side-effects
escribed  as  could  be  spontaneously  expected,  when  exter-
al  applications  of  CHM  were  investigated  or  if  there  was
o  information  provided  about  the  medicinals  used  or  the
umber  of  patients  treated  with  the  different  medicinals.
For  each  study  relevant  to  a  particular  question,  we
xtracted  the  cases  in  which  a  certain  medicinal  in  the
ontext  of  a  formula  was  used.  Subsequently,  the  case  num-
ers  of  the  relevant  studies  were  added.  The  sum  was  the
umber  of  documented  cases  for  which  data  with  respect
o  a  certain  adverse  effect  were  available.  For  each  preg-
ancy  risk  and  each  particular  medicinal,  a  number  of  at
east  100  documented  cases  demonstrating  no  increased
ate  of  adverse  events  was  rated  as  a preliminary  evidence
f  safety.  With  regard  to  teratogenicity,  however,  a  sample
ize  of  300  was  considered  to  be  the  minimum.  The  spon-
aneous  rate  for  major  malformations  lies  at  3  to  4  percent
or  all  newborns.11 Three  hundred  documented  cases  allow
o  exclude  a  2.7-fold  increase  of  this  risk  (at  a  power  of  80
ercent,  95  percent  conﬁdence  level).12 In  our  analysis,  we
ave  listed  only  drugs  that  have  been  tested  in  WS  or  LS,
espectively.  In  the  clinical  studies,  most  formulas  included
urther  drugs  that  we  did  not  analyze.
The  same  methodology  was  applied  to  eligible  studies
rom  CR.  For  this  analysis  only  the  abortion  rate  could  be
valuated  because  other  adverse  events  are  not  adequately
ocumented.  For  those  controlled  trials  that  in  the  meta-
nalyses  of  AR  or  CR  had  shown  a  signiﬁcant  superiority  of
he  combined  therapy  compared  with  Western  drugs  alone,he  sum  may  indicate  the  number  of  documented  cases  in
hich  a  lack  of  abortifacient  effect  of  the  medicinal  in  ques-
ion  is  supported.
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Table  2  ‘‘Signiﬁcant’’  results  in  WS7 regarding  reproductive  toxicology  for  different  periods  of  pregnancy  at  which  the  medicinals  were  given.
Tested  for  period: FR  CRL  HL  SO  SkA  MiA  SB  EPD  LPD  PWG  PWG28
a—b—c b—c b—c b  c—d—e c  d—e d—e d—e d—e d—e
Medicinal  English  name
Atractylodis  macrocephalae Largehead  Atractylodis
Rhizoma  Rhizome  a,c  b,c  b,c  b  d  d,e  e  d,e
Cuscutae Semen Chinese  Dodder  Seed b,c  b,c  b  c  e  d,e  d
Dipsaci Radix Himalayan  Teasel  Root b,c  b,c  b  c  e  d,e  d  d
Taxilli Herba Chinese  Taxillus  Twing a,b,c  b,c  c  e  d  d,e  d
Glycyrrhizae Radix  Liquorice  Root  a  b,c  b,c  b  c  e  d,e
Astragali Radix  Milkvetch  Root  a,c  b  b  b  e  e  d,e
Paeoniae Radix  alba  White  Paeony  Root  a  b,c  e  e  d  d,e  e
Angelicae sinensis  Radix  Chinese  Angelica  a,b,c  b,c  c  b  d  e  d  d,e
Eucommiae Cortex Eucommia  Bark b  b,c  b,c  b  e  d,e
Rehmanniae Radix  praep. Steamed  Rehmannia  Root c  b,c  c  b  c  e  d,e  d
Codonopsis Radix Pilose  Asiabell  Root a,b  c  c  c  d  d
Dioscoreae Radix Common  Yam  Rhizome b,c  b,c  c  d  d  d,e  d,e
Amomi Fructus Villous  Amomum  Fruit a,b  b,c  c  c  e  d  d,e
Rehmanniae Radix Rehmannia  Root c  b  e  d,e  d,e  d,e  d,e
Chuanxiong Rhizoma Szechuan  Lovage  Rhizome a,b,c  b,c  b,c  d  c  e  e  d  d,e
Artemisiae argyi  Folium Chinese  Mugwort  Leaf a,b  b,c  c  c  e  d
Citri reticulatae  Pericarpium Tangerine  Peel c  b  c  c,d  c  d  d,e
Period (a) gestational day (GD) 3—6, period (b) GD 6—8, period (c) GD 8—15, period (d) GD 15 until delivery, period (e) GD 0 until delivery.
FR = fetal resorptions, CRL = crown-rump length, HL = head length, SO = somite, SkA = skeletal anomalies, MiA = other minor anomalies, SB = stillbirth, EPD = early postnatal death, LPD = late
postnatal death, PGW = postnatal weight gain, signiﬁcant results for at least one period (day 1, 7, 14, 28), PWG28 = postnatal weight gain, signiﬁcant results at postnatal day 28.
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esults
e-evaluation  of  WS
n  our  analysis,  we  found  that  WS  does  not  conform  to  the
nternational  ICH  guideline13 which  speciﬁes  the  rat  to  be
he  preferred  animal  species  in  testing  reproductive  toxicity.
n  addition,  the  usual  number  of  cases  in  studies  to  test  for
evelopmental  toxicity  is  set  at  20  dams,14 but  in  WS  the
umber  of  dams  ranged  from  4  to  10.  In  this  respect,  the
robability  of  random  errors  is  high.
The  authors  claimed  that  they  maintained  the  dosage
n  a  range  equivalent  to  the  clinical  dose  for  humans  and
 2-  or  3-fold  increase  thereof,  respectively.  However,  the
asic  study  dose  slightly  exceeded  the  maximum  of  the
quivalent  dose  listed  in  the  Chinese  Pharmacopeia  for  four
rugs.  For  another  ﬁve  drugs  (Cuscutae  Semen,  Taxilli  Herba,
ucommiae  Cortex,  Rehmanniae  Radix  praep.  and  unpre-
ared  Rehmanniae  Radix),  the  dose  level  clearly  exceeded
he  maximum.15
A  closer  look  at  WS  reveals  many  inconsistencies.  For
edicinals  showing  toxic  effects  at  certain  periods  of
dministration  during  pregnancy,  the  toxicity  should  be  par-
icularly  evident  if  the  medicinals  were  taken  throughout
he  entire  pregnancy.  However,  skeletal  anomalies  reported
or  three  medicinals  (Rehmanniae  Radix  praep.,  Chuanxiong
hizoma,  and  Citri  reticulatae  Pericarpium)  given  in  certain
eriods  did  not  arise  when  these  medicinals  were  admin-
stered  throughout  the  entire  pregnancy.  The  same  is  true
or  two  medicinals  (Atractylodis  macrocephalae  Rhizoma
nd  Angelicae  sinensis  Radix)  associated  with  stillbirth,  for
wo  medicinals  associated  with  early  postnatal  death  and
or  seven  medicinals  associated  with  late  postnatal  death
see  Table  2).  It  seems  implausible  that  the  toxic  effects
ppearing  at  one  period  of  pregnancy  can  disappear  after
rolonged  administration  of  the  medicinal.
WS  appears  to  contain  several  serious  biometrical  mis-
akes.  A  total  of  1751  animals  were  treated  with  Chinese
edicinals  (study  group)  but  the  control  group  consisted
f  merely  46  animals.  It  is  very  likely  that  in  a  study
roup  that  is  approximately  38  times  larger  than  the  control
roup,  more  abnormalities  should  arise.  Even  if  the  rates
or  toxic  effects  were  the  same  in  the  study  and  control
roups,  due  to  the  very  large  difference  in  number  of  cases,
bout  38  times  more  events  can  be  expected  for  the  study
roup.
WS  reported  364  signiﬁcant  events.  Of  these,  211  had  a
igniﬁcance  level  of  5%,  47  had  a  signiﬁcance  level  of  1%
nd  106  a  signiﬁcance  level  of  0.1%.  The  large  number  of
igniﬁcant  events  at  0.1%  is  surprising  because  at  this  level
f  signiﬁcance  only  1/10  of  the  signiﬁcant  events  from  a 1%
igniﬁcance  level  is  to  be  expected.
In  Tables  S3—S7  of  WS,  17  substances,  3  doses  and  (total
f  all  tables)  57  criteria  are  listed.  Thus,  17  ×  3  ×  57  =  2907
ests  are  possible.  We  presume  that  all  these  tests  were  cal-
ulated.  But  even  if  only  a  portion  of  these  tests  had  been
alculated,  it  may  be  assumed  that  the  most  ‘‘promising’’
ests  were  included.  Simply  by  applying  the  signiﬁcance
evel  of  5%,  a  total  of  145  (2.907  ×  5%)  false  signiﬁcant
esults  of  the  total  of  364  signiﬁcant  events  are  expected.
nfortunately,  Wang  et  al.  did  not  mention  this  problem  of
ultiple  statistical  tests.
T
m
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For  the  statistical  analysis,  the  authors  have  used  the
ata  from  every  control  group  for  51  tests.  The  multiple  use
f  the  same  control  group  requires  an  adjustment  of  the
-values.  The  authors  did  not  consider  this.
In  addition  to  the  biometric  deﬁciencies,  the  handling  of
he  data  appears  to  be  incorrect.  All  values  for  Atractylodis
acrocephalae  Rhizoma,  including  the  means  and  standard
eviations  are  identical  to  those  of  LS.  The  only  difference
s  that  the  number  of  cases  was  doubled;  the  number  of
ams  was  doubled  from  5  to  10  and  from  4  to  8,  respec-
ively.  The  same  was  done  for  the  numbers  of  offspring.  A
oincidence  can  thus  be  ruled  out.  Nor  is  it  likely  that  the
umbers  in  LS  were  halved.  Doubling  the  number  of  cases
nd  non-disclosure  of  using  results  from  another  study  is  not
 reputable  research  approach.  The  approach  of  this  study
aises  serious  doubts  about  the  reliability  of  its  ﬁndings.
e-evaluation  of  LS
n  the  case  of  Atractylodis  macrocephalae  Rhizoma,  the
aximum  dose  of  12  g  for  humans15 was  used  as  a  baseline
nd  not  the  median  dose  as  claimed.  Therefore,  the  1-  to  3-
mice,  rabbits)  or  6-fold  (rats)  equivalent  dose,  respectively
as  used  in  the  experimental  study.
When  the  results  with  mice  are  analyzed,  a  general
ose-response  relationship  cannot  be  detected,  even  if  only
igniﬁcant  ﬁndings  are  considered.  The  crown-rump  length
as  reduced  if  Atractylodis  macrocephalae  Rhizoma  was
dministered  during  the  period  of  gastrulation  and  increased
hen  administered  in  the  organogenesis  period.  But  the
atter  held  true  only  for  a  1-fold  clinical  dose,  not  at
igher  doses.  If  Atractylodis  macrocephalae  Rhizoma  has
oxic  effects,  the  administration  during  the  entire  preg-
ancy  period  should  permit  a  conclusion.  However,  there
re  13  cases  of  late  postnatal  death  with  the  2-fold  dose,
ut  no  case  with  the  3-fold  dose.  Only  one  single  signiﬁcant
esult  is  noted  for  the  highest  dose:  a  reduced  weight  gain  at
ostnatal  day  7,  but  not  at  postnatal  day  14,  21  or  28.  There
ere  no  signiﬁcant  differences  for  other  parameters  such
s  stillbirths,  postnatal  deaths  and  deformities  compared  to
ontrol.
These  results  are  inconsistent  and  may  be  due  merely  to
hance,  perhaps  caused  by  the  small  case  number  of  5  dams
hich  is  clearly  below  the  customary  number  of  20.  In  rats
nd  rabbits  also,  there  were  no  signiﬁcant  differences  when
he  3-  or  6-fold  ‘‘clinical  dose’’  was  administered.  In  this
ase,  only  3  dams  with  their  offspring  were  tested.
The  results  regarding  congenital  malformations  were  sta-
istically  insigniﬁcant.  Results  that  were  not  signiﬁcant  and
re  based  on  such  small  numbers  of  cases  cannot  establish
 causal  relationship  regarding  teratogenicity.
In summary,  no  valid  conclusions  with  respect  to  embry-
toxic  or  fetotoxic  effects  for  Atractylodis  macrocephalae
hizoma  in  mice,  rats  and  rabbits  can  be  drawn  from  this
tudy.
e-evaluation  of  ARhe  results  of  the  experimental  studies  WS  and  LS  in  ani-
als  can  be  contrasted  with  the  human  experiences  of
dverse  events  in  the  treatment  of  threatened  abortion.  If
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wSafety  aspects  of  Chinese  herbal  medicine  in  pregnancy  
the  increased  resorption  rates  of  fetuses  found  in  WS  for  all
medicinals  except  Dioscoreae  Rhizoma  were  transferable  to
humans,  this  would  mean  that  the  administration  of  these
medicinals  to  pregnant  women,  even  more  a  combination  of
those,  would  have  inevitably  led  to  serial  abortions  or  still-
births,  respectively.  In  AR  the  abortion  rate  of  controlled
trials  with  CHM  alone  was  at  5  to  18.5%  and  in  the  case
studies  at  2 to  20%,  with  combined  therapy  at  0  to  22.3%,
and  with  Western  drugs  alone  at  15  to  33%.  In  this  respect
the  results  are  consistent  and  there  is  no  evidence  of  an
increased  risk  of  abortion  from  Chinese  medicinals.
For  determining  the  frequency  at  which  the  individual
medicinals  are  administrated  to  humans  we  considered  con-
trolled  trials  and  case  control  studies  that  met  our  inclusion
criteria.  The  study  by  Zhang  (2000)*  was  not  included  in
this  and  the  following  analyses,  even  though  it  contains
the  highest  number  of  cases  (n  =  630).  It  was  determined
that  this  study  lacks  sensitivity  for  adverse  events  as  it
documents  considerably  fewer  adverse  events  than  can  be
spontaneously  expected  in  uncomplicated  pregnancy.  The
number  of  cases  treated  for  threatened  miscarriage  and  doc-
umenting  safety  regarding  an  increased  rate  of  abortion  is
shown  in  Table  3.
For  13  of  the  total  17  medicinals  tested  in  WS  and  LS,
respectively,  in  mice,  documented  experiences  on  humans
with  case  numbers  of  at  least  100  are  available  (range  of
100  to  1502  cases).  For  one  medicinal  (Chuanxiong  Rhi-
zoma),  there  are  only  44  documented  cases;  for  3  more
medicinals,  no  cases  exist  because  these  drugs  are  not  indi-
cated  for  treatment  of  threatened  abortion  (Citri  reticulatae
Pericarpium,  Artemisiae  argyi  Folium,  and  raw  Rehmanniae
Radix).  For  11  medicinals,  case  numbers  of  more  than  500
exist,  for  six  medicinals  more  than  1000.  Thus,  for  most  of
the  medicinals  tested  in  WS  and  LS  there  is  quite  a  high
number  of  cases  documenting  the  safety  with  respect  to
abortion.
Growth  retardation  (in  terms  of  crown-rump  length,
head  length,  somite)  is  present  in  WS  for  all  tested  medici-
nals  for  one  or  two  of  the  testing  periods.  For  documented
medicinals  no  evidence  of  fetal  growth  retardation  was
observed  in  humans.  For  11  medicinals,  the  number  of  cases
exceeded  100  (Atractylodis  macrocephalae  Rhizoma,  Cuscu-
tae  Semen,  Dipsaci  Radix,  Taxilli  Herba,  Glycyrrhizae  Radix,
Astragali  Radix,  Paeoniae  Radix  alba,  Angelicae  sinensis
Radix,  Eucommiae  Cortex,  Dioscoreae  Rhizoma  and  Amomi
Fructus).  For  six  medicinals,  smaller  case  numbers  or  no
results  are  available  (Table  4  and  Supplementary  Table  S3).
WS  found  increased  rates  of  early  or  late  postnatal
death  in  most  of  the  tested  medicinals.  The  only  exceptions
were  Taxilli  Herba,  Eucommiae  Cortex  and  Citri  reticu-
latae  Pericarpium.  For  the  comparison  with  experiences  on
humans,  the  parameters  were  neonatal  health  and  develop-
ment.  Three  studies  of  AR  fulﬁlled  the  requirements  deﬁned
for  this  evaluation.  Relevant  case  numbers  of  more  than
100  documented  cases  were  reached  only  for  Atractylodis
macrocephalae  Rhizoma,  Dipsaci  Radix  and  Taxilli  Herba
(Table  4  and  Supplementary  Table  S4).
With  respect  to  teratogenicity,  among  the  studies  of
AR  only  one  unspeciﬁed  malformation  was  reported  in  the
case  series  Zhou  (2006)*.  With  a  sample  size  of  40  pregnant
women  treated  with  Chinese  medicine,  this  case  (corre-
sponding  to  2.5%)  is  not  signiﬁcant.  Because  the  study’s
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bservation  period  ends  at  delivery,  it  does  not  meet  our
nclusion  requirements.  For  individual  medicinals,  only  small
umbers  of  cases  (0  to  109)  are  available  (Table  4  and  Sup-
lementary  Table  S5).  These  are  insufﬁcient  for  a  safety
ssessment  regarding  congenital  malformations.  CHM  was
dministered  in  the  study  conducted  by  He  (1997)*  between
he  6th  and  the  12th  week  of  pregnancy,  and  in  the  study
onducted  by  Wang  and  Li  (2000)*  between  the  5th  and  20th
eek.  This  partly  exceeds  the  sensitive  period  for  malfor-
ations.
For  all  tested  medicinals,  WS  found  a ‘‘signiﬁcant’’
mpairment  of  postnatal  weight  gain  on  at  least  one  ref-
rence  date.  Taking  into  consideration  only  the  last  studied
eference  date  (postnatal  day  28),  there  were  ‘‘signiﬁcant’’
eight  deﬁcits  noted  for  seven  medicinals.  In  humans,  how-
ver,  the  three  studies  with  an  observation  period  of  one
ear  or  more  listed  in  Table  4  and  S4  showed  no  postnatal
evelopmental  disorders.  Sufﬁcient  sample  sizes  of  over  100
re  documented  for  Atractylodis  macrocephalae  Rhizoma,
ipsaci  Radix  and  Taxilli  Herba.
e-evaluation  of  CR
n  CR  a  meta-analysis  was  undertaken  which  included  ﬁve
andomized  controlled  trials.  The  combination  therapy  of
HM  and  Western  drugs  versus  Western  drugs  alone  was
igniﬁcantly  superior  in  terms  of  the  main  outcome  vari-
ble  ‘‘absence  of  abortion’’.  Of  these  ﬁve  studies,  one
rovided  no  information  about  the  administered  medicinals
nd  another  used  an  external  application.  We  calculated  the
ase  numbers  of  the  remaining  three  studies.  As  to  Zhong’s
2002)*  study,  only  the  case  number  for  the  combined  ther-
py  was  included.
The  resulting  case  numbers  for  individual  medicinals
ere  pooled  with  the  case  numbers  of  the  AR  meta-analysis,
s  well  for  combined  therapy  of  CHM  and  Western  drugs.  Two
tudies  of  AR  were  not  included  due  to  an  insufﬁcient  follow-
p  period.  Table  5  shows  the  number  of  documented  cases
or  medicinals  for  which  a  signiﬁcantly  reduced  rate  of  mis-
arriage  was  shown  as  part  of  a  combined  therapy  versus
estern  drugs  alone.  This  is  a  much  stricter  criterion  than
pplies  to  the  case  numbers  in  Table  3.  These  results  can
e  used  to  argue  against  the  transferability  of  a  potential
etal  die-off  in  mice  to  humans.  Eleven  drugs  were  present
n  case  numbers  of  100  or  more,  namely  Atractylodis  macro-
ephalae  Rhizoma,  Cuscutae  Semen,  Dipsaci  Radix,  Taxilli
erba,  Glycyrrhizae  Radix,  Paeoniae  Radix  alba,  Eucommiae
ortex,  Rehmanniae  Radix  praeparata,  Codonopsis  Radix,
ioscoreae  Rhizoma,  and  Amomi  Fructus.  Due  to  the  lack
f  precise  information  for  other  medicinals,  for  these  only
inimum  values  that  lie  below  100  could  be  estimated.
iscussion
he  authors  of  WS  attempted  to  identify  risks  for  the  appli-
ation  of  Chinese  medicinals  during  pregnancy.  The  authors
ere  interested  in  conducting  a  carefully  planned  study,  for
xample  they  tried  to  use  doses  akin  to  those  administered
o  humans.
However,  their  work  contains  serious  biometric  ﬂaws
uch  as  in  the  scheduling  and  evaluation  of  the  study  and
960
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Table  3  Number  of  cases  on  which  single  medicinals  were  used  in  relevant  studies  of  AR9 showing  no  evidence  of  failure  of  intervention  at  threatened  miscarriage.
Study  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  ˙
Number  of  cases  CM  54  45  100  44  40  131  56  58  118  58  68  47  86  60  30  305  67  34  40  61  41  1543
Formula ZXBTD  BSGTD  JWATD  TSPSP  STP  ZNBTF  YSGCD  TEAP  STP  STP  BYD  STP  STP  STP  STP  ATD  ATD  ATD  STP  STP  WZD
Atraclyl. macr.  Rhz.  54  100  44  40  131  56  118  58  68  47  86  60  30  305  67  34  40  61  1399
Cuscutae Sem.  54  45  100  44  40  131  56  58  118  58  68  47  86  60  30  305  67  34  40  61  1502
Dipsaci Rd.  54  45  100  44  40  131  56  118  58  68  47  86  60  30  305  67  34  40  61  1444
Taxilli Hb. 54  45  44  40  131  56  118  58  68  47  86  60  30  305  67  34  40  61  1344
Glycyrrhizae Rd.  54  45  44  305  67  34  549
Astragali Rd.  54  44  131  56  58  305  67  34  749
Paeoniae Rd.  alba  54  45  100  44  56  58  305  67  34  763
Angelicae sinen.  Rd.  54  44  58  305  67  34  562
Eucommiae Cort.  45  100  44  40  56  118  58  47  86  60  30  305  67  34  40  61  41  1232
Rehmanniae Rd.  prp.  44  56  100
Codonopsis Rd.  45  100  44  131  68  388
Dioscoreae Rhz.  45  40  56  118  58  47  86  60  30  305  67  34  40  61  1047
Amomi Fr.  54  100  40  118  58  47  86  60  30  40  61  694
Chuanxiong Rhz.  44  44
Only studies were included that exhibited a sufﬁcient long follow-up period. Only medicinals are presented that are tested in WS. Studies: (1) Song and Zhu (2007), (2) Li (2006), (3) He
and Che (2007), (4) Yue (2009), (5) Zhou (2006), (6) Xu (2008), (7) Ye and Qiu (2008), (8) Luo (2007), (9) Chou (2002), (10) Xu (2001), (11) Chen and Yun (1999), (12) Cui (1998), (13) Kang
(1998), (14) Chen (1997), (15) He (1997), (16) Zhou (1997), (17) Zhu and Li (1992), (18) Tian and Li (1991), (19) Li (1989), (20) Wang and Wang (1987), (21) Wu (1987). Formulas: ATD—–An
Tai Decoction, BSGTD—–Bu Shen Gu Tai Dec., BYD—–Bao Yun Dec., JWATD—–Jiu Wei An Tai Dec., STP—–Shou Tai Pill, TEAP—–Tai Er An Pill, TSPSP—–Tai Shan Pan Shi Pill, WZD—–Wu Zi Dec.,
YSGCD—–Yi Shen Gu Chong Dec., ZNBTF—–Zi Ni Bao Tai Formula, ZXBTD—–Zhi Xue Bao Tai Dec. CM = Chinese herbal therapy (CHT) alone or combined medicine (CHT plus Western drugs).
References of the studies are quoted in Supplementary Table S1.
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Table  4  Sum  of  frequencies  the  various  medicinals  were  used  in  relevant  studies  of  AR9 apparently  documenting  safety  with
regard to  the  speciﬁc  outcome.
Medicinal  No  increased
rate  of  abortion
Fetal  growth  or
birth  weight
Neonat.  health
and  develop.
Congenital  malform.
and  neonat.  develop.
Atraclyl.  macr.  Rhz.  1399  562  176  109
Cuscutae Sem.  1502  483  97  30
Dipsaci Rd.  1444  562  176  109
Taxilli Hb.  1344  613  176  109
Glycyrrhizae  Rd.  549  121  67  0
Astragali Rd. 749  172  67  0
Paeoniae Rd.  alba 763  172  67  0
Angelicae sinen.  Rd. 562  121  67  0
Eucommiae Cort. 1232  470  97  30
Rehmanniae  Rd.  prp.  100  51  0  0
Codonopsis Rd.  388  0  0  0
Dioscoreae Rhz.  1047  429  97  30
Amomi Fr.  694  416  30  30
Rehmanniae  Rd.  0  0  0  0
Artemisiae argyi  Fol.  0  0  0  0
Chuanxiong Rhz.  44  0  0  0
Citri reticulatae  Peric.  0  0  0  0
Only medicinals are presented that are tested in WS.  The number of cases is summed up from the relevant studies.
Details are presented in Supplementary Tables S3—S5.
Table  5  Number  of  cases  of  studies  showing  a  signiﬁcant  lower  abortion  rate  for  combined  medicine  (CHT  plus  Western  drugs)
versus Western  drugs  alone  at  threatened  abortion.
Study  Li  (2006)† He  and  Che
(2007)†
Yue  (2009)† Chen  (2002)†† Lv  (2007)†† Zhong  (2002)†† Number  of
cases  Total
Number  of  cases  CM  45  100  44  51  58  30  Total
Atraclyl. macr.  Rhz.  100  44  n.d.  58  30  ≥232
Cuscutae  Sem.  45  100  44  51  58  30  328
Dipsaci Rd.  45  100  44  51  58  30  328
Taxilli Hb.  45  44  51  58  30  228
Glycyrrhizae Rd.  45  44  n.d.  58  ≥147
Astragali Rd.  44  n.d.  ≥44
Paeoniae Rd.  alba  45  100  44  n.d.  n.d.  n.d.  ≥189
Angelicae  sinen.  Rd.  44  n.d.  ≥44
Eucommiae  Cort.  45  100  44  n.d.  ≥189
Rehmanniae  Rd.  prp. 44  58  102
Codonopsis Rd.  45  100  44  n.d.  58  30  ≥277
Dioscoreae  Rhz.  45  58  30  133
Amomi Fr.  100  n.d.  n.d.  n.d.  ≥100
Rehmanniae  Rd.  n.d.  n.d.  ≥0
Artemisiae  argyi  Fol.  n.d.  n.d.  ≥0
Chuanxiong  Rhz.  44  44
Citri reticulatae  Peric.  n.d.  n.d.  ≥0
‘‘Number of cases total’’ is the number of cases from relevant AR9 and CR10 studies summed up.
Studies exhibiting an insufﬁcient follow-up were excluded. Only medicinals are presented that are tested in WS and LS. Some studies
use more medicinals in addition to the basic formula, whose frequency is not deﬁned (‘‘n.d.’’), case numbers are minimum numbers
here. CM = CHT alone or combined medicine (CHT plus Western drugs). References of the studies are quoted in Supplementary Tables S1
and S2.
† Studies from the AR meta-analysis.
†† Studies from the CR meta-analysis.
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rregularities  in  handling  of  data.  The  number  of  cases  is
mall.  These  factors  prevent  us  from  accepting  the  results
s  valid.  The  absence  of  a  dose-response  relationship  makes
he  results  appear  even  more  implausible.  Thus,  we  con-
lude  that  the  study  is  not  suitable  for  using  the  results
o  derive  pregnancy  risks  in  humans  for  the  tested  Chinese
edicinals.  Similarly,  because  of  several  implausibilities  and
nsigniﬁcant  results,  LS  cannot  be  considered  qualiﬁed  for
rawing  valid  conclusions  with  respect  to  embryotoxicity  or
etotoxicity  of  Atractylodis  macrocephalae.
Several  results  of  WS  and  LS  differ  from  the  outcomes  of
ther  research.  WS  found  developmental  disorders  with  the
se  of  Taxilli  Herba  in  mice  embryos.  Liu  et  al.  tested  this
edicinal  in  groups  of  12  pregnant  rats  and  did  not  detect
hese  disorders.  There  were  neither  divergences  in  terms
f  body  weight,  body  length,  or  tail  length  of  the  embryos
ompared  to  control  nor  were  there  skeletal  anomalies.16
he  conclusions  of  LS  clash  with  results  from  another  study
or  which  a  detailed  abstract  was  published.17 This  study
xamined  the  pregnancy  risks  of  Atractylodis  macrocepha-
ae  Rhizoma  in  groups  of  17  or  18  mice.  An  aqueous  extract
f  Atractylodis  macrocephalae  Rhizoma  was  administered
rally  in  doses  of  2,  8  and  32  g/kg  from  day  6  to  15  of
estation.  Distilled  water  served  as  the  control.  The  study
ound  no  signiﬁcant  differences  between  the  varying  doses
f  Atractylodis  macrocephalae  Rhizoma  and  the  control  with
espect  to  the  incidence  of  fetal  resorptions,  dead  fetuses,
bvious  malformations  or  skeletal  abnormalities.
In  addition,  the  results  of  WS  and  LS  appear  to  contra-
ict  the  results  obtained  in  treatment  of  humans,  in  so  far
s  the  administration  of  the  tested  medicinals  has  been
ocumented  in  Chinese  controlled  trials  or  case  series  and
ere  included  in  AR.9 For  the  parameters  abortion  risk,
etal  growth  retardation,  postnatal  survival  and  postnatal
evelopment,  the  number  of  at  least  100  cases  was  rated  as
inimum  to  make  a  preliminary  statement  on  the  safety  of
hinese  medicinals.  For  the  parameter  abortion  rate,  most
rugs  are  reaching  high  numbers  of  cases  of  up  to  more  than
500.  Thus,  administration  of  the  medicinals  in  question  is
nlikely  to  increase  the  rate  of  abortion.  This  statement  is
urther  supported  by  studies  from  CR10 on  the  treatment
f  threatened  miscarriage.  When  combining  the  results  of
he  two  meta-analyses  with  the  strict  criterion  of  signiﬁ-
ant  superiority  of  CHM  as  adjunctive  therapy  compared  to
estern  drugs  alone,  eleven  out  of  17  drugs  achieved  a  num-
er  of  100  documented  cases  or  more.  A  further  review  on
HM  for  recurrent  miscarriage  evaluating  studies  different
rom  those  of  CR  showed  that  CHM  or  CHM  combined  with
estern  drugs  was  superior  to  Western  drugs  alone  in  most
ases.  There  was  no  evidence  of  an  elevated  abortion  rate
y  CHM.18
Fewer  cases  are  available  for  analysis  to  answer  the
uestions  of  fetal  growth  retardation,  postnatal  deaths
nd  postnatal  developmental  disorders.  However,  the  doc-
mented  experiences  in  humans  appear  to  disprove  the
ccurrence  of  such  effects.  For  teratogenicity,  the  number
f  cases  was  insufﬁcient  to  ascertain  the  absence  of  this  risk.
therwise,  it  is  worth  noting  that  in  AR  there  are  no  positive
lues  of  teratogenicity  for  the  medicinals  tested.
Generally,  the  transferability  of  results  from  exper-
mental  animal  studies  to  the  therapeutic  situation  in
umans  is  questionable.11,19 Species-related  bioavailability,
n
u
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etabolism,  and  sensitivity  can  differ  greatly  and  —  given
he  differing  embryogenesis  —  can  lead  to  different  effects.
ince  there  is  a  threshold  dose  for  teratogenic  effects,
esults  from  high  doses  often  used  in  animal  studies  are
ot  generally  predictive  for  therapeutic  doses  of  humans.
here  are  several  substances  which  have  proven  terato-
enic  effects  in  animals  which  do  not  exhibit  this  property
n  humans.  For  example,  aspirin  is  known  to  cause  cardiac
efects  in  rats  and  rhesus  monkeys  but  shows  no  terato-
enicity  in  humans.  Insulin  is  teratogenic  in  rats,  mice  and
abbits,  but  is  regarded  the  treatment  of  choice  for  diabetes
uring  pregnancy  in  humans.14 Of  165  compounds  which  are
egarded  as  non-teratogenic  to  humans,  the  tests  were  actu-
lly  negative  only  in  80  percent  for  monkeys,  70  percent
or  rabbits,  50  percent  for  rats  and  in  only  35  percent  for
amsters  and  mice.20 There  is  also  evidence  of  teratogenic
r  embryotoxic  and  fetotoxic  effects  from  animal  studies
or  food  constituents,  e.g.  for  caffeine20 and  for  alkaloids
ccurring  in  potatoes  which  however,  pose  no  known  risk  to
umans.21—23
For  natural  medicines  with  a  long  history  of  use,  experi-
ental  animal  studies  are  likely  to  raise  more  questions  than
rovide  answers.  Instead,  more  data  from  human  studies
re  needed.  Intervention  trials  on  the  safety  of  drugs  during
regnancy  are  forbidden  for  ethical  reasons.  Human  data
n  teratogenicity  are  derived  primarily  from  cohort  studies
ith  large  numbers  of  cases  in  which  a  relationship  between
he  occurrence  of  congenital  malformations  and  the  use  of  a
ertain  drug  can  be  established.  These  studies  document  the
utcomes  of  drugs  that  were  taken  without  or  despite  knowl-
dge  of  an  existing  pregnancy  and  compare  these  data  with
he  frequencies  of  malformations  with  those  of  non-exposed
regnancies.
At  least  one  cohort  study  has  shown  a  risk  of  congeni-
al  malformations  for  the  use  of  CHM  in  humans.24 Coptidis
hizoma  (huang  lian) was  associated  with  increased  mal-
ormations  of  the  nervous  system  and  the  external  genital
ystem.  The  formula  an  tai  yin  led  to  increased  malforma-
ions  of  the  musculoskeletal  and  connective  tissue  and  the
ye.  (The  composition  of  an  tai  yin  varies  between  sources.)
n  children  whose  mothers  had  taken  Coptidis  Rhizoma  dur-
ng  pregnancy,  the  same  authors  were  able  to  observe  an
ncrease  in  cancer  cases,  particularly  of  the  CNS,  after  a
ean  follow-up  period  of  14.9  years.25
Usually,  the  use  of  natural  remedies  during  pregnancy  is
ot  documented.  The  reasons  for  this  are,  among  others,
hat  these  remedies  are  considered  less  risky  and  that  their
onsumption  frequently  occurs  without  medical  supervision.
s  a  result,  little  objective  data  about  their  teratogenicity
nd  other  pregnancy  risks  are  available.19,26—28 And  in  fact,
ven  less  data  are  available  than  for  pharmaceutical  drugs
hat  are  relatively  new  on  the  market.11 Nevertheless,  the
xperience  collected  over  time  is  of  some  value,  even  in
erms  of  teratogenicity,  since  CHM  has  been  used  under  mod-
rn  scientiﬁc  supervision  for  about  two  generations.  Even
uring  this  time,  most  teratogens  of  Western  drugs  were
rst  noticed  through  case  reports  and  clinical  case  studies
nd  not  by  animal  testing.19While  conventional  medicine  often  takes  the  view  that
atural  remedies  are  to  be  avoided  during  pregnancy
ntil  their  safety  has  been  proven,29,30 others  argue  that
raditionally-used  remedies  with  few  side-effects  should  not
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be  banned  until  there  is  clear  evidence  of  risk.26 In  the  case
of  dietary  supplements,  the  European  Food  Safety  Authoritiy
(EFSA)  has  established  a  category  in  which  a  substance  is  pre-
sumed  to  be  safe  and  does  not  require  further  safety  assays
if  no  adverse  effects  have  been  reported  after  long-term  use
on  large  populations31:  ‘‘Depending  on  the  botanical  ingre-
dient  and  its  uses,  there  are  circumstances  under  which  no
additional  data  are  judged  necessary  for  the  safety  evalu-
ation,  i.e.  a  presumption  of  safety  would  be  applied.  This
would  be  the  case  whenever  available  data  would  allow  to
conclude  that  exposure  to  known  levels  of  the  botanical
ingredient  has  occurred  in  large  population  groups  for  many
years  without  reported  adverse  effects.’’
On  the  other  hand,  experience  alone  is  not  sufﬁcient  to
detect  seldom-occurring  risks.  The  obvious  teratogenicity
of  Coptidis  Rhizoma  was  only  recognized  by  a  large  epi-
demiological  study.  Even  if  this  cannot  be  regarded  as  a
deﬁnitive  statement,  this  risk  must  be  perceived  and  be
closely  observed  as  long  as  no  mitigating  data  are  avail-
able.  Unfortunately,  this  study  is  an  exception  and  there
is  a  continuing  lack  of  knowledge  about  the  teratogenicity
of  Chinese  medicinals.  For  most  of  conventional  drugs,  too,
there  is  considerable  uncertainty  regarding  their  pregnancy
risks,  even  for  those  that  are  sometimes  administered  dur-
ing  pregnancy.  It  is  estimated  that  about  98  percent  of  the
drugs  approved  between  2000  and  2010  in  the  U.S.  fall  into
the  category  of  ‘‘undetermined  teratogenic  risk’’.32
Therefore,  as  for  chemical  drugs,  Chinese  medicinals
should  only  be  administered  to  pregnant  women  after  a
careful  beneﬁt-risk  assessment.  Medicines  should  only  be
applied  if  there  is  an  unequivocal  indication,  especially
during  the  ﬁrst  trimester.  The  same  applies  for  fertility
treatment,  which  often  extends  into  the  pregnancy.  The
important  period  of  organogenesis  in  humans  is  between
gestational  day  22  and  55.  However,  it  is  known  that  some
teratogens  can  cause  malformations  if  administered  prior  to
this  period.14 For  example,  even  one  year  after  discontinu-
ing  the  anti-psoriatic  agent  acitretin,  every  20th  child  could
still  be  affected  by  malformations.33,34
Limitations
One  limitation  of  the  risks  assessment  is  the  fact  that  the
effects  as  well  as  the  side-effects  of  medicinals  may  depend
on  the  type  of  combination  in  which  they  are  adminis-
tered.  However,  to  assess  each  individual  combination  by
itself  would  require  a  great  deal  more  data.  This  type  of
data  is  generally  unavailable.  Furthermore,  in  some  studies,
the  standard  formula  was  modiﬁed  by  adding  or  subtrac-
ting  medicinals  individually,  a  common  practice  in  Chinese
herbal  medicine.  At  present,  any  evaluation  of  commonly-
used  medicinals  is  only  possible  by  relying  on  the  sum  of
experiences  collected  through  the  application  in  different
combinations.
The  data  extracted  from  AR  and  CR  are  based  on
low-quality  studies.  Therefore,  only  limited  conclusions
regarding  both  efﬁcacy  and  safety  can  be  made  from  these.
Furthermore,  the  Chinese  medicinals  were  used  at  different
times  during  pregnancy,  in  some  cases  outside  the  sensitive
phase  for  malformations.  For  a  few  studies  no  data  for  the
time  of  administration  are  available.  On  the  other  hand,963
ome  data  are  based  on  a  high  number  of  cases  and  are  very
onsistent,  which  partly  outweighs  the  limitations.
onclusion
aking  the  viewpoint  that  documented  clinical  experience
s  of  some  notable  value  for  safety  evaluation,  we  believe
hat  for  those  medicinals  with  higher  case  numbers  show-
ng  an  unremarkable  course  of  pregnancy,  the  data  suggest
hat  a  preliminary  positive  safety  statement  is  warranted.
egarding  teratogenicity,  there  are  insufﬁcient  data  for  evi-
ence  of  safety.  Therefore,  for  most  Chinese  medicinals,  the
ituation  remains  similar  to  that  of  the  majority  of  chemical
rugs,  namely,  that  neither  the  safety  nor  the  risk  during
regnancy  can  be  deﬁnitely  ascertained.  Further  studies  on
he  risks  of  Chinese  medicinals  during  pregnancy,  chieﬂy  epi-
emiological  studies  and  documented  administrations,  are
rgently  needed  to  investigate  the  issue  of  possible  terato-
enicity.
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